The scale gives you one number. It cannot tell you what happened to your blood sugar, blood pressure, kidneys or strength.
GLP-1 medicines help control blood sugar and appetite. Different medicines in this group are used for type 2 diabetes, weight management, or both.
If you take a GLP-1 medicine, keep the weight conversation. Add another question: “What are we following besides my weight?”
In this article
What did the new GLP-1 pill study find?
ACHIEVE-4 compared a daily pill, orforglipron (Foundayo), with long-acting insulin injections. The 2,749 participants had type 2 diabetes, overweight or obesity, and a higher chance of heart or blood-vessel problems. Results were reported September 30, 2026.
The paper’s first author is Klara R. Klein, MD, PhD, an assistant professor of medicine at the University of North Carolina School of Medicine.
The pill passed the study’s heart-safety test. Researchers checked that serious heart and blood-vessel problems did not increase beyond a limit set before the trial. Blood sugar and weight also fell more with the pill.
This did not prove the pill prevents more heart attacks or strokes than insulin. It also does not mean the pill has no risks.
Three questions a headline can blur
When you read that a treatment is good for the heart, ask what the study actually measured.
- Did it pass a heart-safety test? The study checks for an increase in serious heart problems compared with another treatment. Passing this test does not mean zero risk.
- Did health numbers improve? Lower blood sugar, blood pressure or cholesterol can matter. But better numbers alone do not prove that a treatment prevents heart attacks or strokes.
- Did it prevent serious problems? This takes a study showing fewer heart attacks, strokes or deaths from heart and blood-vessel disease. The medicine, dose and people studied all matter.
A medicine can improve weight and blood tests without having established every longer-term benefit people hope for.
Some GLP-1 medicines have shown heart benefits
Some medicines in this group have been shown to reduce serious heart problems. For example, the FDA has approved semaglutide tablets (Rybelsus) to lower the chance of heart attack, stroke or death from heart and blood-vessel disease in adults with type 2 diabetes who are at high risk.
That finding does not automatically apply to another medicine or to everyone taking a medicine for weight loss. Ask: “What benefits have been shown for my medicine in people with a health history like mine?”
Sources: 3
What should we follow besides weight?
Use these as conversation starters. Your clinician can choose the tests, goals and follow-up that fit your history; taking a GLP-1 does not mean everyone needs the same testing schedule.
- Blood sugar: What is my A1C, the measure of average blood sugar over the past few months? Has it changed?
- Blood pressure: What do my readings show? If I feel dizzy or lightheaded, should we review my medicines?
- Cholesterol: What has changed, and do I still need a separate cholesterol treatment plan?
- Kidney health: Do I need a blood test to check how well my kidneys filter, a urine test for protein, or both?
- Heart risk: Do my previous heart problems, diabetes, kidney disease, pregnancy complications or family history change the goals of treatment?
- Nutrition: Am I eating enough to meet my needs? Are side effects making food or fluids difficult?
- Muscle and strength: How are stairs, carrying groceries and getting up from a chair feeling? What is our plan to support strength?
Keep strength and nourishment in the plan
When you feel less hungry, getting enough food and nutrients can take more planning. Expert guidance recommends following what you eat, side effects, strength and everyday activities, alongside weight.
Ask about a food plan and strength exercises, such as using weights or exercise bands, that fit your abilities. How much protein you need depends on your health, including any kidney disease. Protein supplements alone are not enough to protect muscle.
Tell your prescriber if nausea, vomiting or diarrhea makes it hard to eat or drink. Persistent fluid loss can affect the kidneys. Do not change treatment on your own because of a headline.
Bring your own before and after
Write down the medicine and dose, why it was prescribed, when you started, any recent results and what feels different in daily life. Include what you want to keep doing comfortably.
Then ask: “If my weight changes, how will we know whether my health and strength are improving too?”
Evidence behind the article
Sources and editorial review
Sources checked:
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4)Klara R. Klein and colleagues · The Lancet · 2026
- Detailed ACHIEVE-4 results and statistical qualificationsEli Lilly · Sponsor’s results announcement · September 30, 2026
- Rybelsus prescribing information: cardiovascular indicationU.S. Food and Drug Administration · 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisoryAmerican College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society · May 30, 2025
- Chronic Kidney Disease Tests & DiagnosisNational Institute of Diabetes and Digestive and Kidney Diseases · Accessed October 1, 2026
- A Guide to Cardiovascular-Kidney-Metabolic HealthAmerican Heart Association · Accessed October 1, 2026
Eli Lilly funded ACHIEVE-4. Treatment was assigned by chance; participants knew which medicine they received. The heart-safety result met the trial’s set limit, but its range of uncertainty included both benefit and harm (hazard ratio 0.84; 95% confidence interval 0.59–1.20; safety margin 1.8).
Fewer deaths were reported with the pill, but that analysis did not account for the extra chance of a positive finding when many comparisons are made. It is not firm proof that this pill makes people live longer.
The nutrition and follow-up discussion draws on separate guidance. ACHIEVE-4 did not establish that orforglipron preserves muscle. These findings should not be generalized to people without diabetes or to every GLP-1 medicine.
Independent clinical review is identified only when it has been completed and approved in writing. No external reviewer or organization is implied. Sources do not imply endorsement of HEART RESERVE.
